4/A: Monopar Therapeutics Director Sells Shares
Insider Transaction (Form 4/A)
Kim R Tsuchimoto, a Director of Monopar Therapeutics, sold 4,090 shares of common stock on August 26, 2026.
Summary
- Option exercise/conversion: acquired 2,055 Common Stock at $30.00 ($61,650) on August 26, 2026; holds 2,055 after (Direct).
- Option exercise/conversion: acquired 2,035 Common Stock at $14.00 ($28,490) on August 26, 2026; holds 4,090 after (Direct).
- Open-market sale: disposed of 485 Common Stock at $108.83 ($52,783) on August 26, 2026; holds 3,605 after (Direct).
- Open-market sale: disposed of 615 Common Stock at $109.56 ($67,379) on August 26, 2026; holds 2,990 after (Direct).
- Open-market sale: disposed of 700 Common Stock at $110.65 ($77,455) on August 26, 2026; holds 2,290 after (Direct).
- Open-market sale: disposed of 1,098 Common Stock at $111.84 ($122,800) on August 26, 2026; holds 1,192 after (Direct).
- Open-market sale: disposed of 602 Common Stock at $112.93 ($67,984) on August 26, 2026; holds 590 after (Direct).
- Open-market sale: disposed of 590 Common Stock at $113.84 ($67,166) on August 26, 2026 (Direct).
- Option exercise/conversion: acquired 2,055 Stock Option on August 26, 2026; holds 6,165 after (Direct).
- Option exercise/conversion: acquired 2,035 Stock Option on August 26, 2026; holds 8,140 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $455,567 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Kim R Tsuchimoto — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-26 | Option exercise/conversion | Common Stock | 2,055 | $30 | $61.6K | 2,055 |
| 2026-08-26 | Option exercise/conversion | Common Stock | 2,035 | $14 | $28.5K | 4,090 |
| 2026-08-26 | Open-market sale | Common Stock | 485 | $109 | $52.8K | 3,605 |
| 2026-08-26 | Open-market sale | Common Stock | 615 | $110 | $67.4K | 2,990 |
| 2026-08-26 | Open-market sale | Common Stock | 700 | $111 | $77.5K | 2,290 |
| 2026-08-26 | Open-market sale | Common Stock | 1,098 | $112 | $122.8K | 1,192 |
| 2026-08-26 | Open-market sale | Common Stock | 602 | $113 | $68.0K | 590 |
| 2026-08-26 | Open-market sale | Common Stock | 590 | $114 | $67.2K | 0 |
| 2026-08-26 | Option exercise/conversion | Stock Option | 2,055 | — | — | 6,165 |
| 2026-08-26 | Option exercise/conversion | Stock Option | 2,035 | — | — | 8,140 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-26 | Option exercise/conversion (2,055 shares) |
| 2026-08-26 | Option exercise/conversion (2,035 shares) |
| 2026-08-26 | Open-market sale (485 shares) |
| 2026-08-26 | Open-market sale (615 shares) |
| 2026-08-26 | Open-market sale (700 shares) |
| 2026-08-26 | Open-market sale (1,098 shares) |
| 2026-08-26 | Open-market sale (602 shares) |
| 2026-08-26 | Open-market sale (590 shares) |
| 2026-08-26 | Option exercise/conversion (2,055 shares) |
| 2026-08-26 | Option exercise/conversion (2,035 shares) |
Keywords
insider transaction, Form 4/A, MNPR, Monopar Therapeutics, bearish, Kim R Tsuchimoto
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.